AiomNews Speciale Tumore del Seno e Biopsia Liquida N. 29

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 – metastatic breast cancer treated with CDK4/6 inhibitors

Background: Bone-only HR+/HER2 – metastatic breast cancer generally has a favourable prognosis, but some patients develop visceral metastases. We aimed to quantify visceral conversion and identify reproducible baseline correlates during CDK4/6 inhibitor (CDK4/6i) therapy.
Methods: This multicentre retrospective cohort included 692 patients treated with palbociclib, ribociclib, or abemaciclib plus endocrine therapy as first- or second-line treatment across 24 Italian centres … Continua a leggere

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial

Purpose: To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC).
Methods: In this phase III, open-label, multicenter trial (ClinicalTrials.gov identifier: NCT06968585), conducted at 57 centers in China, adult patients with HER2-positive, unresectable/metastatic BC who had received prior trastuzumab and a taxane were randomly assigned (1:1) … Continua a leggere

Purpose: The EMERALD trial led to the approval of elacestrant for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC) with disease progression following at least one line of endocrine therapy (ET). Subgroup analyses provided evidence suggesting that elacestrant enables ET sequencing in the second line before other targeted combinations, which could delay chemotherapy-based regimens … Continua a leggere

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0

Purpose: To provide recommendations on use of medical therapies for patients with stage I-III hormone receptor-positive, HER2-negative breast cancer.
Methods: An Expert Panel including patient representation completed a systematic review of the evidence and formulated recommendations for practice. Eligible studies included patients with stage I-III hormone receptor-positive … Continua a leggere